A) Zyprexa B) Prolixin C) Risperdal D) Geodon
A) Invega B) Abilify C) Clozaril D) Zyprexa
A) Seroquel B) Invega C) Abilify D) Zyprexa
A) Seroquel B) Zyprexa C) Abilify D) Risperdal
A) Risperdal B) Geodon C) Seroquel D) Abilify
A) Olanzapine B) Clozapine C) Ziprasidone D) Quetiapine
A) Ziprasidone B) Aripriprazole C) Paliperidone D) Risperidone
A) Seroquel B) Geodon C) Clozaril D) Risperdal
A) Paliperidone B) Aripiprazole C) Ziprasidone D) Clozapine
A) Paliperidone B) Risperdone C) Olazapine D) Quetiapine
A) Clozapine and Risperadone B) Risperidone and Paliperidone C) Aripiprazole and Paliperidone D) Clozapine and Aripiprazole
A) 1-3 B) 4-5 C) 2-5 D) 1
A) 24 B) 12 C) 18 D) 6
A) TRUE B) FALSE
A) Minimize side effects of medication B) Foster patients' medication compliance C) Develop more adaptive coping skills D) Prevent relapse into another psychotic episode
A) several weeks after discontinuation of medication B) one year after discontinuation of medication C) six months after discontinuation of medication D) directly after discontinuation of medication
A) Artane B) Thorazine C) Clozaril D) Symmetrel
A) weight gain more common B) increased effectiveness for positive, negative, and disorganized symptoms C) enhanced efficacy in treatment-resistant patients D) tardive dyskinesia more common
A) Haloperiodol B) Prochlorperazine C) Risperidone D) Clozapine
A) Anxiolitics B) Stimulants C) Anticonvulsants D) Alcohol
A) Merperidine B) Beta blockers C) Halperiodol D) Alcohol
A) Antacids B) Beta blockers C) Anticonvulsants D) Nicotine
A) Beta blockers B) SSRIs C) Alcohol D) Tricyclic antidepressants
A) TRUE B) FALSE
A) Drug holidays B) Tobacco use C) Male gender D) Alcohol use
A) TRUE B) FALSE
A) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. B) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia. C) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. D) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications.
A) Akathesia B) Acute dystonia C) Akinesia D) Ataxia
A) Gynecomastia B) Neuroleptic Malignant Syndrome C) Postural hypotension D) Agranulocytosis
A) TRUE B) FALSE
A) TRUE B) FALSE
A) block D2 receptors in the pituitary gland and decrease prolactin secretion. B) block D2 receptors in the pituitary gland and inhibit prolactin secretion. C) antagonize the normal dopamine-mediated inhibition of prolactin release. D) agonize the normal dopamine-mediated inhibition of prolactin release.
A) hungry hungry hippos B) molecular structure C) neuroendocrine changes D) receptor binding and DA turnover
A) Butyrophenones B) Thioxanthenenes C) Sleepykoaladones D) Phenothiazines
A) Potent; low; higher B) Potent; low; lower C) Weak; high; higher D) Weak; high; lower
A) Formal thought disorder B) Anhedonia C) Delusions D) Hallucinations
A) Neurological disorders B) Endocrine disorders C) All of the above D) Autoimmune diseases E) Metabolic disorders
A) All of the above B) Opioids C) Hallucinogens D) Stimulants E) Alcohol
A) FALSE B) TRUE
A) disorganized symptoms of Schizophrenia. B) All of the above. C) positive symptoms of Schizophrenia. D) negative symptoms of Schizophrenia.
A) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. C) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. D) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. B) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine.
A) increased tap dancing B) increased release of dopamine C) increased rates of synthesis D) increased rates of firing
A) piperideines B) piperazines C) thioxanthenes D) aliphatics
A) genecomastia B) galactorrhea C) menstrual irregularity D) all of the above
A) Cogentin (benztropine) B) Inapsine (droperiodol) C) Artane (trihexphenidyl) D) Symmetrel (amantadine) E) Benadryl (diphenhydramine)
A) FALSE B) TRUE
A) actual impact at the biological level B) polypharmacy C) comparative lack of EPS D) superior impact on positive symptoms
A) Clozaril B) Haldol C) Abilify D) Invega
A) Clorazil B) Geodon C) Seroquel D) Risperdal |